Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium
Executive Summary
Group of sponsors, insurers and health systems will draw on datasets of de-identified pharmacy and medical claims data to monitor effectiveness and safety of novel biologics and their corresponding biosimilars.
You may also be interested in...
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.